Roche Announces New Four-Year Data of Lunsumio for Relapsed or Refractory Follicular Lymphoma
2024-12-10 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, December 10, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today, regarding four-year data from overseas Phase II study (GO29781) of Lunsumio ® (generic name: mosunetuzumab) for relapsed or refractory follicular lymphoma. The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting. Please refer to the link below for details of the press release: New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma https://www.roche.com/media/releases/med-cor-2024-12-10 Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗